Please login to the form below

Not currently logged in
Email:
Password:

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

GW Pharma sativex nabiximols MS

Almirall has launched its cannabinoid treatment Sativex for moderate to severe spasticity in multiple sclerosis (MS) patients in Italy.

The drug, developed by GW Pharmaceuticals, was approved by Italian authorities in May and comes to the market with a reimbursed priced that GW said was “consistent with the reimbursed … price in Spain”.

Sativex (nabiximols) is licensed to treat moderate to severe spasticity in MS patients who have not responded adequately to other anti-spasticity medication and will be reimbursed by the Italian authorities as a Class H (hospital dispensed) medicine.

It makes Sativex, which is administered as an oromucosal spray, the first medicine containing cannabinoids to be made available in Italy for the treatment of spasticity in MS.

Justin Gover, GW's CEO, said: "As one of the largest markets in Europe, the launch of Sativex in Italy is a key milestone in the commercialisation of this important new medicine. Italy represents yet another addition to the growing number of countries in Europe in which Sativex is now available to treat MS spasticity, a particularly debilitating symptom of MS that is not adequately treated with currently available medications.

"With a total of 21 countries that have now approved Sativex for use in the treatment of MS spasticity, and a further nine countries in which regulatory submissions are ongoing, we look forward to a series of further commercial launches over the coming twelve months."

The drug contains cannabinoids extracted from cannabis sativa plants grown and processed under strictly controlled conditions. It is comprised of two primary active components, THC (delta-9-tetrahidrocannabinol) and CBD (cannabidiol).

GW said that in order to monitor therapeutic accuracy and appropriateness, a National Register has been established in which patients in Italy who are treated with Sativex will be enrolled.

Sativex has been given a rolling launch in Europe, with GW partnering with Bayer in the UK and non-European markets. The company has also signed deals with Novartis and Otsuka.

9th July 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics